Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced toda
Successful Live Case Demonstration of Elixir Medical’s Fully Bioresorbable DESolve NXT Plus Novolimus Eluting Coronary Scaffold System at TCT
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced toda
Elixir Medical Announces Excellent, 3-Year Clinical and Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
Golden Tube Visualization, Low MACE and Lumen Gain Sustained Long-Term Sunnyvale, Calif. – October 15, 2015 — Elixir Medical Corporation, a developer of products that combin
Elixir Medical Announces Excellent, 3-Year Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
Successful Live Case of DESolve® 100 implantation at Elixir Symposium at EuroPCR 2015 Sunnyvale, Calif. – May 20, 2015 — Elixir Medical Corporation, a developer of products